Effect of iguratimod on diclofenac metabolism by CYP2C9 in rats and human recombinant CYP2C9 yeast cells

Iguratimod (IGU, also known as T-614), a novel disease modifying antirheumatic drug intended to cure patients with rheumatoid arthritis (RA). The purpose of this study is to evaluate the effect of IGU on the pharmacokinetics of CYP2C9 probe drug diclofenac and its metabolite 4′-hydroxy diclofenac in...

Full description

Bibliographic Details
Main Authors: Muhammad Usman, Zhu Zhen-Han, Chang Ze-Na, Han Jun-Ping, Qian Wen, Yang Chang-Qing, Nishikawa Miyu, Sakaki Toshiyuki
Format: Article
Language:English
Published: Universidade de São Paulo
Series:Brazilian Journal of Pharmaceutical Sciences
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502019000100523&lng=en&tlng=en